Evidence map›Paper›PMID 29138948›Full record

ArticleInternational journal of clinical oncology2018

Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).

Yuji Miyamoto, Akihito Tsuji, Hiroaki Tanioka, Soichiro Maekawa, Hirofumi Kawanaka, Masaki Kitazono, Eiji Oki, Yasunori Emi, Hidetsugu Murakami, Yutaka Ogata and 6 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Yuji MiyamotoDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.
Akihito TsujiDepartment of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Hiroaki TaniokaDepartment of Medical Oncology, Okayama Rousai Hospital, Okayama, Japan.
Soichiro MaekawaDepartment of Surgery, Munakata Medical Association Hospital, Fukuoka, Japan.
Hirofumi KawanakaNational Hospital Organization, Beppu Medical Center, Beppu, Japan.
Masaki KitazonoGastroenterological Surgery, Nanpuh Hospital, Kagoshima, Japan.
Eiji OkiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yasunori EmiDepartment of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Hidetsugu MurakamiDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Yutaka OgataDepartment of Surgery, Kurume University Medical Center, Kurume, Japan.
Hiroshi SaekiGastroenterological Surgery, Nanpuh Hospital, Kagoshima, Japan.
Mototsugu ShimokawaDepartment of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Shoji NatsugoeDepartment of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Yoshito AkagiDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Hideo BabaDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan. hdobaba@kumamoto-u.ac.jp.
Yoshihiko MaeharaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication, in Abstract, the sentence that reads as, "Oral S-1 at a dose of 80 mg/m

Identifiers

PMID29138948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.